Richard A. Heyman, Director at Enliven Therapeutics, Inc. (ELVN), sold 5,650 shares at $27.51 ($155K) on 2024-10-04, disclosed to the SEC on 2024-10-08.
Scheduled sale ($155k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.51 | 2,825 | $78K | 50.0% |
| 2 | $27.51 | 2,825 | $78K | 50.0% |
| Total | $27.51 avg | 5,650 | $155K | 100% |
| Filing → |
| ELVN | SELL | 2026-02-19 | $32K | — | Filing → |
| ELVN | SELL | 2026-01-22 | $33K | — | Filing → |
| ORIC | SELL | 2026-01-20 | $80K | — | Filing → |